Aimery de Gramont

Summary

Country: France

Publications

  1. doi request reprint Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
    Isabelle Baumgaertner
    Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
    Clin Colorectal Cancer 9:E5-10. 2010
  2. ncbi request reprint The evolving role of oxaliplatin in the management of colorectal cancer
    A de Gramont
    Hopital Saint Antoine, Paris, France
    Colorectal Dis 5:10-9. 2003
  3. ncbi request reprint Adjuvant therapy for stage II and III colorectal cancer
    Aimery de Gramont
    Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Semin Oncol 34:S37-40. 2007
  4. ncbi request reprint Adjuvant therapy of stage II and III colon cancer
    Aimery de Gramont
    Hopital Saint Antoine, GERCOR, Paris, France
    Semin Oncol 32:11-4. 2005
  5. ncbi request reprint Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Oncology 69:46-56. 2005
  6. ncbi request reprint Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    A de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
    J Clin Oncol 18:2938-47. 2000
  7. ncbi request reprint FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
  8. ncbi request reprint Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    May Mabro
    Department of Medical Oncology, Hopital Saint Antoine, Paris, France
    Am J Clin Oncol 26:254-8. 2003
  9. ncbi request reprint Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
  10. ncbi request reprint Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 25:3224-9. 2007

Detail Information

Publications31

  1. doi request reprint Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
    Isabelle Baumgaertner
    Department of Hepatogastroenterology, Hopital Pitie Salpetriere, Paris, France
    Clin Colorectal Cancer 9:E5-10. 2010
    ..These analyses compare the safety and efficacy of 2 forms (levogyre [L] and dextro-levogyre [DL]) of leucovorin (LV) when used with 5-fluorouracil (5-FU) for the adjuvant treatment of patients with stage II and III colon cancer...
  2. ncbi request reprint The evolving role of oxaliplatin in the management of colorectal cancer
    A de Gramont
    Hopital Saint Antoine, Paris, France
    Colorectal Dis 5:10-9. 2003
    ..The first of these studies, MOSAIC, has already shown a very encouraging 23% decrease in the risk of relapse at 3 years (P = 0.002) with FOLFOX4 compared to LV5FU2...
  3. ncbi request reprint Adjuvant therapy for stage II and III colorectal cancer
    Aimery de Gramont
    Groupe Coopérateur Multidisciplinaire en Oncologie, Hopital Saint Antoine, Service de médecine interne oncologie, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Semin Oncol 34:S37-40. 2007
    ..Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy...
  4. ncbi request reprint Adjuvant therapy of stage II and III colon cancer
    Aimery de Gramont
    Hopital Saint Antoine, GERCOR, Paris, France
    Semin Oncol 32:11-4. 2005
    ..Ongoing important issues to be addressed relate to the optimal schedule and/or choice of chemotherapeutic regimens, and the efficacy of the combination of molecular agents with conventional chemotherapy...
  5. ncbi request reprint Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris, France
    Oncology 69:46-56. 2005
    ..001). Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy...
  6. ncbi request reprint Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    A de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, Paris, France
    J Clin Oncol 18:2938-47. 2000
    ..This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point...
  7. ncbi request reprint FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    J Clin Oncol 22:229-37. 2004
    ..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
  8. ncbi request reprint Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    May Mabro
    Department of Medical Oncology, Hopital Saint Antoine, Paris, France
    Am J Clin Oncol 26:254-8. 2003
    ..FOLFIRI-2 achieved a good rate of response and stabilization in heavily pretreated patients despite significant toxicity...
  9. ncbi request reprint Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    Anne Marie Coudray
    INSERM U482, Signal Transduction and Cellular Functions in Diabetes and Digestive Cancers, Paris, France
    Int J Oncol 27:553-61. 2005
    ..These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers...
  10. ncbi request reprint Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
    Aimery de Gramont
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 25:3224-9. 2007
    ....
  11. ncbi request reprint Pemetrexed in patients with gastrointestinal carcinoma
    Aimery de Gramont
    Hopital Saint Antoine, Service de médecine interne oncologie, Paris, France
    Semin Oncol 29:42-9. 2002
    ....
  12. ncbi request reprint OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 24:394-400. 2006
    ..This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin...
  13. doi request reprint Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    Thierry Andre
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    J Clin Oncol 27:3109-16. 2009
    ..7% at 48 months. CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease...
  14. doi request reprint Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
    Benoist Chibaudel
    Hopital Saint Antoine, Paris Cedex 12, France
    J Clin Oncol 27:5727-33. 2009
    ....
  15. ncbi request reprint Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
    Thierry Andre
    Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
    J Clin Oncol 25:3732-8. 2007
    ....
  16. ncbi request reprint Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells
    Eric Raymond
    INSERM U482, Hopital Saint Antoine, Paris, France
    Int J Oncol 21:361-7. 2002
    ..These results argue in favor of clinical trials of chemotherapy combining MTA with oxaliplatin or irinotecan (CPT-11), for the treatment of patients with colon cancer...
  17. ncbi request reprint [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer]
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12
    Bull Cancer 93:S11-5. 2006
    ..Combinations of capecitabine and oxaliplatine are also promising. The next step will come from the two new targeted therapies in metastatic colorectal cancer, directed against EGFR and VEGF...
  18. pmc Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set
    Aimery de Gramont
    Hopital Saint Antoine, Group Hospitalier Pitie Salpetriere, Paris, France
    J Clin Oncol 28:460-5. 2010
    ..New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association...
  19. ncbi request reprint Colorectal cancer: integrating oxaliplatin
    Christophe Louvet
    Service d Oncologie, Hopital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris, France
    Curr Treat Options Oncol 4:405-11. 2003
    ..The tolerance of the oxaliplatin/5-FU combination allows for design regimens integrating new drugs, such as biologic modifiers...
  20. ncbi request reprint Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)
    Christophe Louvet
    Service de médecine interne oncologie, Hopital St Antoine, 184 rue du fbg St Antonie, 75012, Paris, France
    Cancer Invest 21:14-20. 2003
    ..Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma...
  21. ncbi request reprint Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission
    Christophe Tournigand
    Service d Oncologie Medicale, Hopital Saint Antoine, Paris, France
    Gynecol Oncol 91:341-5. 2003
    ....
  22. ncbi request reprint Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial
    Thierry Andre
    Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
    J Clin Oncol 21:2896-903. 2003
    ....
  23. ncbi request reprint [Colon cancer: what is new in 2004?]
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Bull Cancer 91:75-80. 2004
    ..Shrinkage of tumours after administration of preoperative chemotherapy and availability of ablative techniques (radiofrequency and cryotherapy) now allow to treat with curative intent metastases initially considered as non-resectable...
  24. ncbi request reprint An overview of adjuvant systemic chemotherapy for colon cancer
    Thierry Andre
    Service d Oncologie, Hopital Tenon, Paris, France
    Clin Colorectal Cancer 4:S22-8. 2004
    ..Future studies in adjuvant therapy for colon cancer will explore oxaliplatin and 5-FU with or without antiangiogenesis or anti-epidermal growth factor agents...
  25. ncbi request reprint Pemetrexed in advanced colorectal cancer
    Christophe Louvet
    Hopital St Antoine, Service de Medecine Int Onc, Paris, France
    Oncology (Williston Park) 18:56-62. 2004
    ..All of these trials include vitamin supplementation. A phase III trial comparing the every-3-week pemetrexed/oxaliplatin regimen with FOLFOX4 as first-line treatment will be initiated if the outcome of the phase II trial is encouraging...
  26. ncbi request reprint Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
    Frédérique Maindrault-Goebel
    Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
    Eur J Cancer 41:2262-7. 2005
    ..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence...
  27. ncbi request reprint First-line therapy for advanced colorectal cancer
    Aimery de Gramont
    Service de médecine interne oncologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
    Curr Oncol Rep 7:167-72. 2005
    ..Furthermore, we fear that limited financial resources will also influence the management of this disease...
  28. ncbi request reprint Targeted agents for adjuvant therapy of colon cancer
    Aimery de Gramont
    GERCOR Groupe Coopérateur Multidisciplinaire en Oncologie and Hôpital Saint Antoine, Paris, France
    Semin Oncol 33:S42-5. 2006
    ..Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial...
  29. doi request reprint Stage II and stage III colon cancer: treatment advances and future directions
    Benoit Rousseau
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, France
    Cancer J 16:202-9. 2010
    ..Adjuvant therapy in elderly patients is another matter of debate due to the lack of survival advantage in the recent trials...
  30. ncbi request reprint Rapid evolution in colorectal cancer: therapy now and over the next five years
    Aimery de Gramont
    Hopital Saint Antoine, 184 Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Oncologist 10:4-8. 2005
    ..South San Francisco, CA, http://www.gene.com), and on the ability of applied genomics to distinguish between high- and low-risk populations...
  31. ncbi request reprint Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors
    Pierre Blanchard
    Service d Oncologie Medicale, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012, Paris, France
    Gynecol Oncol 104:41-5. 2007
    ..Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy...